Production (Stage)
Outlook Therapeutics, Inc.
OTLK
$1.90
$0.031.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.39M | 33.39M | 28.25M | 20.68M | 20.58M |
| Gross Profit | -33.39M | -33.39M | -28.25M | -20.68M | -20.58M |
| SG&A Expenses | 38.65M | 36.09M | 29.94M | 27.10M | 25.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.44M | 82.99M | 71.70M | 61.28M | 59.86M |
| Operating Income | -76.44M | -82.99M | -71.70M | -61.28M | -59.86M |
| Income Before Tax | 21.12M | -46.81M | -75.36M | -94.05M | -159.13M |
| Income Tax Expenses | 2.80K | 2.80K | 2.80K | 2.80K | 2.80K |
| Earnings from Continuing Operations | 21.12 | -46.81 | -75.37 | -94.05 | -159.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.12M | -46.81M | -75.37M | -94.05M | -159.13M |
| EBIT | -76.44M | -82.99M | -71.70M | -61.28M | -59.86M |
| EBITDA | -76.32M | -82.87M | -71.59M | -61.19M | -59.78M |
| EPS Basic | 1.37 | -5.14 | -6.72 | -7.95 | -11.48 |
| Normalized Basic EPS | 0.70 | -0.82 | -1.79 | -2.54 | -4.40 |
| EPS Diluted | -1.43 | -7.94 | -9.51 | -10.75 | -11.48 |
| Normalized Diluted EPS | 0.61 | -0.91 | -1.88 | -2.63 | -4.40 |
| Average Basic Shares Outstanding | 102.06M | 85.46M | 74.24M | 63.51M | 53.13M |
| Average Diluted Shares Outstanding | 104.31M | 87.71M | 76.49M | 65.76M | 53.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |